Modified Exosome Conjugation for Dendritic Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tumor exosome-based cancer vaccines face sub-optimal activation of dendritic cells (DCs) for antigen processing and presentation, leading to inadequate cytotoxic T lymphocyte (CTL) responses and antitumor efficacy, despite the inclusion of adjuvants, due to the lack of a facile method to conjugate adjuvants to nanosized tumor exosomes.
Innovation Solution
Modified exosomes with surface proteins or lipids covalently linked to immunomodulatory molecules, such as toll-like receptor agonists or cytokines, using click chemistry, enhance DC activation and antigen presentation by metabolic glycan labeling and conjugation, enabling improved CTL responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adjuvants are mixed with tumor exosomes, then DC activation is improved, but the integration is sub-optimal due to lack of covalent conjugation method
Solution Approach 1:
The patent applies preliminary action by first introducing a chemical tag (e.g., azide group) onto the exosome surface before conjugation. This pre-modification enables subsequent efficient coupling with adjuvants bearing complementary groups (e.g., DBCO), creating a stable conjugate. This two-step approach (tagging then conjugating) resolves the contradiction by providing a reliable, scalable method to achieve strong adjuvant-exosome integration without complex direct conjugation chemistry.
Solution Approach 2:
The patent uses an intermediary approach by introducing a chemical tag as a mediator between the exosome surface and the adjuvant. The tag (e.g., azide group) on the exosome reacts with a linker molecule (e.g., DBCO-adjuvant) to form a stable covalent bond. This intermediary mechanism enables reliable adjuvant conjugation to nanosized exosomes, solving the manufacturing difficulty while ensuring strong DC activation through proper adjuvant integration.
2Productivity
If tumor exosomes are used as vaccine, then antigen presentation is enabled, but CTL responses are insufficient due to sub-optimal DC activation
Solution Approach 1:
The patent applies merging by covalently conjugating adjuvants directly to the exosome surface, creating a unified adjuvant-exosome conjugate. This merged structure ensures that adjuvant and antigen are delivered together to DCs, synergistically enhancing both DC activation and subsequent CTL response. The stable conjugation prevents separation during biological processes, ensuring reliable immune activation while maximizing productivity.
Solution Approach 2:
The patent creates a composite material system by combining exosomes with adjuvants through covalent conjugation. The resulting adjuvant-exosome conjugate functions as a hybrid vaccine platform that integrates the antigen-presenting capabilities of exosomes with the immune-stimulating properties of adjuvants. This composite approach simultaneously improves DC activation reliability and CTL response productivity.
3Ease of manufacture
If conventional mixing of adjuvant and exosome is used, then formulation is simple, but synergy is insufficient due to distinct trafficking profiles
Solution Approach 1:
The patent applies preliminary action by performing covalent conjugation of adjuvants to exosomes during the formulation process. This pre-conjugation ensures that adjuvant and exosome are permanently associated before administration, overcoming the problem of distinct trafficking profiles that limits synergy in simple mixtures. The conjugated structure maintains formulation simplicity while ensuring reliable synergistic effect through controlled co-delivery to DCs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified exosomes significantly enhance DC activation and antigen processing, resulting in enhanced CTL responses and antitumor efficacy against lymphoma and melanoma, with a >175-fold improvement in DC activation compared to traditional methods.
Implementation Method 1
the covalent link includes a glycan moiety, for example the surface protein is a glycoprotein and the covalent link between the protein and the immunomodulatory molecule includes a sugar moiety. In other examples, the surface lipid is a glycolipid and the covalent link between the lipid and the immunomodulatory molecule includes a sugar moiety. In some examples, the surface protein or lipid is linked to the immunomodulatory molecule by click chemistry (e.g., azide-alkyne click chemistry, tetrazine-norbornene click chemistry, tetrazine-cyclooctene click chemistry, or maleimide-thiol click chemistry).
Implementation Method 2
Modified exosomes with surface proteins or lipids covalently linked to immunomodulatory molecules, such as toll-like receptor agonists or cytokines, using click chemistry, enhance DC activation and antigen presentation by metabolic glycan labeling and conjugation
Data Source
AI summary
Provided herein are exosomes (such as modified exosomes) that include or express one or more surface proteins that are covalently linked to an immunomodulatory molecule or a therapeutic molecule. In particular examples, the exosomes are from a cancer cell, a stem cell, or an immune cell. Also provided are methods of making and using the modified exosomes, for example for treating cancer.